Skip to main content
Oxford University Hospitals NHS Foundation Trust

Help us improve this website


Take our short survey - you can enter our prize draw.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Oxford researchers test ‘Viagra’ drug to prevent recurrent strokes

News Image

Researchers at the John Radcliffe Hospital have begun a clinical trial to assess whether the drug sildenafil, more commonly known by its commercial name Viagra, could improve blood flow to the brain and so have the potential to reduce damage to small blood vessels in the brain and prevent strokes.

Chronic damage to small blood vessels deep in the brain is found in half of patients over the age of 60 and almost all patients over the age of 80, and is responsible for up to a third of strokes and around 40 percent of dementia.

Dr Alastair Webb, of the University of Oxford’s Wolfson Centre for Prevention of Stroke and Dementia, based at the John Radcliffe, is leading the study. He explained: “There is limited evidence for how this small vessel disease develops and no specific treatment.” 
“We aim to test whether sildenafil has the potential to reduce small vessel damage.”

Potential explanations for how small vessel disease develops include: a greater change in blood pressure with each beat of the heart (pulsatility), which hits the brain with increased force with each beat; or a reduced ability of the blood vessels in the brain to adapt to changes in the environment, also known as their reactivity.

Sildenafil is currently used to open up blood vessels in patients with erectile difficulties or poor blood supply to the lungs. 

This trial, which is supported by the NIHR Oxford Biomedical Research Centre and the Wellcome Trust, will test sildenafil against a placebo tablet and against a similar drug called cilostazol in 75 patients who have had a stroke or mini-stroke previously and who also have evidence of injury to their small blood vessels on a brain scan.

“We will compare three weeks of treatment with sildenafil, cilostazol and the placebo to assess whether they improve pulsations in blood flow or reactivity of blood vessels in the brain,” Dr Webb said.

This will be measured using an ultrasound scanner whilst participants breathe air or a mixture of air and six percent carbon dioxide. To understand why any changes occur, the team will also measure the stiffness of arteries, the blood pressure at the heart and the body's blood pressure control mechanisms. 

Finally, 30 participants will have similar tests whilst undergoing an MRI brain scan to test changes in blood flow to the brain in even greater detail.

This study will test whether these 'vasodilating' medications – drugs that widen the blood vessels - are good candidates to reduce the progression of small vessel disease in future clinical trials, and so reduce the risk of stroke and dementia. 

“This would be the first specific treatment for this very common condition that is responsible for a significant amount of disability,” Dr Webb explained.

The trial is expected to last around two years.

Photo by Robina Weermeijer on Unsplash